For research use only. Not for therapeutic Use.
LDK378 (Ceritinib)(CAT: I000197) is a highly potent and selective inhibitor of anaplastic lymphoma kinase (ALK), widely used in oncology research. By targeting ALK, it effectively disrupts downstream signaling pathways involved in cell proliferation, survival, and metastasis, making it a critical tool for studying ALK-driven cancers, such as non-small cell lung cancer (NSCLC). LDK378 exhibits high efficacy against ALK mutations associated with drug resistance, supporting its relevance in preclinical studies of targeted cancer therapies. With exceptional potency, specificity, and stability, it is ideal for in vitro and in vivo applications, advancing research in personalized cancer treatment and ALK-targeted drug discovery.
| Catalog Number | I000197 |
| CAS Number | 1032900-25-6 |
| Synonyms | 5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine |
| Molecular Formula | C₂₈H₃₆ClN₅O₃S |
| Purity | ≥95% |
| Target | Anaplastic lymphoma kinase (ALK) |
| Solubility | DMSO: ≥ 5.6 mg/mL (Need ultrasonic) |
| Storage | 3 years -20C powder |
| IC50 | 0.2 nM [1] |
| IUPAC Name | 5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine |
| InChI | InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34) |
| InChIKey | VERWOWGGCGHDQE-UHFFFAOYSA-N |
| SMILES | CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl |
